2,442 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 2,442 shares of the specialty pharmaceutical company's stock, valued at approximately $301,000.

Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after acquiring an additional 121 shares in the last quarter. Cooper Financial Group increased its stake in shares of Jazz Pharmaceuticals by 3.7% in the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company's stock valued at $534,000 after acquiring an additional 156 shares in the last quarter. Coldstream Capital Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock valued at $259,000 after acquiring an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after acquiring an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,253 shares of company stock worth $1,001,434. Company insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research analyst reports. Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Needham & Company LLC reissued a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Piper Sandler reissued an "overweight" rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $177.00.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $0.25 during midday trading on Tuesday, reaching $121.43. The company had a trading volume of 538,623 shares, compared to its average volume of 486,035. The company's 50 day moving average price is $122.66 and its 200 day moving average price is $114.87. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $7.34 billion, a P/E ratio of 17.10, a P/E/G ratio of 0.88 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.